Literature DB >> 3931615

The value of visual evoked potential as a screening test in neurofibromatosis.

B Jabbari, C G Maitland, L M Morris, J Morales, C H Gunderson.   

Abstract

Pattern reversal visual evoked potential (VEP) test was performed in 30 asymptomatic patients with neurofibromatosis (NF). All patients had normal visual acuity, visual fields, and ophthalmoscopic examination results. Pattern reversal VEP was abnormal in eight patients (26%). Seven of these patients had computed tomographic scans with reformated orbital views. Orbital computed tomographic scans were abnormal in six patients and in each case showed enlargement of the optic nerve on the side of VEP abnormality. Our data indicate that pattern reversal VEP is a valuable screening test in asymptomatic patients with NF. Because of the high incidence of VEP abnormality in such patients, VEP abnormality must be interpreted cautiously when a patient with NF is suspected of having other diseases or disorders that potentially affect the visual pathways.

Entities:  

Mesh:

Year:  1985        PMID: 3931615     DOI: 10.1001/archneur.1985.04060100054022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 2.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

3.  Neurofibromatosis Type 1: Ocular Electrophysiological and Perimetric Anomalies.

Authors:  Marcella Nebbioso; Antonietta Moramarco; Alessandro Lambiase; Sandra Giustini; Marco Marenco; Emanuele Miraglia; Pasquale Fino; Chiara Iacovino; Ludovico Alisi
Journal:  Eye Brain       Date:  2020-10-21

4.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

5.  Early diagnosis of optic glioma in children with neurofibromatosis type 1.

Authors:  L N Rossi; G Pastorino; G Scotti; M Gazocchi; M M Maninetti; C Zanolini; A Chiodi
Journal:  Childs Nerv Syst       Date:  1994-09       Impact factor: 1.475

6.  Electrophysiological monitoring in a patient with an optic nerve glioma.

Authors:  Phillip Moradi; Anthony G Robson; Geoffrey E Rose; Graham E Holder
Journal:  Doc Ophthalmol       Date:  2008-02-27       Impact factor: 2.379

7.  Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings.

Authors:  Benedetto Falsini; Lucia Ziccardi; Ilaria Lazzareschi; Antonio Ruggiero; Luca Placentino; Anna Dickmann; Lucia Liotti; Marco Piccardi; Emilio Balestrazzi; Cesare Colosimo; Concezio Di Rocco; Riccardo Riccardi
Journal:  J Neurooncol       Date:  2008-02-02       Impact factor: 4.130

8.  Visual evoked potentials in children with neurofibromatosis type 1.

Authors:  Alessandro Iannaccone; Richard A McCluney; Vickie R Brewer; Peter H Spiegel; June S Taylor; Natalie C Kerr; Enikö K Pivnick
Journal:  Doc Ophthalmol       Date:  2002-07       Impact factor: 2.379

9.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  A M Lund; F Skovby
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

10.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.